Instil Bio Files 8-K
Ticker: TIL · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financial-exhibits
TL;DR
Instil Bio dropped an 8-K, likely with news. Check it out.
AI Summary
Instil Bio, Inc. filed an 8-K on August 15, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific details about the nature of the disclosure or financial information within the provided text.
Why It Matters
This filing indicates Instil Bio is making a regulatory disclosure and submitting financial exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which often contains material information, but the specific content is not detailed here, necessitating further review.
Key Numbers
- 001-40215 — SEC File Number (Instil Bio's SEC filing identifier)
- 83-2072195 — IRS Employer Identification No. (Instil Bio's tax identification number)
Key Players & Entities
- Instil Bio, Inc. (company) — Registrant
- 0001789769-24-000090 (filing_id) — Accession Number
- August 15, 2024 (date) — Report Date
- 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 (address) — Principal Executive Offices
FAQ
What specific information is being disclosed under Regulation FD?
The provided text of the 8-K filing does not specify the details of the Regulation FD disclosure.
What are the key financial statements or exhibits being filed?
The filing indicates that Financial Statements and Exhibits are being submitted, but their specific content is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 15, 2024.
What is Instil Bio, Inc.'s principal executive office address?
Instil Bio, Inc.'s principal executive office is located at 3963 Maple Avenue, Suite 350, Dallas, Texas 75219.
What is the SIC code for Instil Bio, Inc.?
The Standard Industrial Classification (SIC) code for Instil Bio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-15 17:00:13
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market L
Filing Documents
- til-20240815.htm (8-K) — 32KB
- finalinstilbiocorppres20.htm (EX-99.1) — 13KB
- finalinstilbiocorppres20001.jpg (GRAPHIC) — 69KB
- finalinstilbiocorppres20002.jpg (GRAPHIC) — 266KB
- finalinstilbiocorppres20003.jpg (GRAPHIC) — 105KB
- finalinstilbiocorppres20004.jpg (GRAPHIC) — 114KB
- finalinstilbiocorppres20005.jpg (GRAPHIC) — 111KB
- finalinstilbiocorppres20006.jpg (GRAPHIC) — 102KB
- finalinstilbiocorppres20007.jpg (GRAPHIC) — 120KB
- finalinstilbiocorppres20008.jpg (GRAPHIC) — 145KB
- finalinstilbiocorppres20009.jpg (GRAPHIC) — 74KB
- finalinstilbiocorppres20010.jpg (GRAPHIC) — 98KB
- finalinstilbiocorppres20011.jpg (GRAPHIC) — 81KB
- finalinstilbiocorppres20012.jpg (GRAPHIC) — 129KB
- finalinstilbiocorppres20013.jpg (GRAPHIC) — 119KB
- finalinstilbiocorppres20014.jpg (GRAPHIC) — 115KB
- finalinstilbiocorppres20015.jpg (GRAPHIC) — 50KB
- 0001789769-24-000090.txt ( ) — 2517KB
- til-20240815.xsd (EX-101.SCH) — 2KB
- til-20240815_lab.xml (EX-101.LAB) — 22KB
- til-20240815_pre.xml (EX-101.PRE) — 13KB
- til-20240815_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure Instil Bio, Inc. (the "Company") from time to time presents and/or distributes to the investment community presentations related to its business. A copy of its most recent presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. The information herein and in the exhibit hereto is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 SYN-2510 Program Overview 104 the cover page of this report has been formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: August 15, 2024 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)